Neurocrine Adds Epilepsy Assets From Xenon
Xenon will have freedom to focus on later-stage pipeline
Neurocrine plans to advance XEN901 into Phase II in a rare pediatric epilepsy indication while eyeing opportunity in adult focal epilepsy. Xenon increases its runway to develop a pair of mid-stage epilepsy drugs.
